Navigation Links
Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
Date:10/6/2009

open additional study centers for the ongoing pharmacokinetic study, to undertake a clinical trial for L-DOS47 in Poland, and to undertake a European Phase III trial of Topical Interferon Alpha-2b. Forward-looking statements and information can be identified by the use of forward-looking terminology such as "future", "next", "intends", "2010", "2011", "expects", "projects", "plan", "anticipates", "scheduled", or any other variations thereon, or that events or conditions "will", "may" or "could", "would", or "should" occur or be achieved, or comparable terminology referring to future events or results. Although Helix believes that the expectations reflected in such forward-looking statements and information are reasonable, such statements and information involve risks and uncertainties, and undue reliance should not be placed on such statements and information. Certain material factors or assumptions are applied in making forward-looking statements and providing forward-looking information, and actual results may differ materially from those expressed or implied in such statements and information. Important factors that could cause actual results to differ materially from these forward-looking statements and information include, without limitation, the Company's continuing need for additional capital, which may not be available in a timely manner or at all and which if not obtained will have a material adverse impact on the Company and its ability to continue, or if not obtained in a timely manner, may result in the Company's having to discontinue or delay one or more of its product development programs or other initiatives; the ongoing impact of the global economic downturn and credit crisis which have and continue to negatively affect the availability and terms of debt and equity financings; uncertainty whether an IND will be compiled or filed for Topical Interferon Alpha-2b or L-DOS47 as currently planned or at all, or if filed, whether the Company will be permi
'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
2. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
3. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
4. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
5. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
6. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
7. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
8. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
11. Immunosyn Announces Biozyme Labs Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF-1019
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014 Scott Steiger ... most of the world. As an engineer for the past 20 ... member of the military service. He,s been to six of the ... Photo - http://photos.prnewswire.com/prnh/20141126/161076 Photo - http://photos.prnewswire.com/prnh/20141126/161077 ... for travelers, he has a pretty good idea of what,s required. ...
(Date:11/26/2014)... -- Zynerba Pharmaceuticals , Inc., a specialty pharmaceutical ... cannabinoid treatments, today announced that the company will present ... The conference will be held December 2 to 3, ... York . Zynerba,s Chairman and CEO, Armando ... December 2. To listen to a webcast ...
(Date:11/26/2014)... , Nov. 26, 2014 The ... at a rate of 4%, with world market ... Kalorama Information. MRI and other types of medical ... and treatment of numerous medical conditions in children ... and techniques. Kalorama,s report, Medical Imaging Markets ...
Breaking Medicine Technology:Steiger Has Created the First Pill Case Specifically Designed For Travel 2Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2Kalorama: Steady Growth in the Medical MRI Market 2Kalorama: Steady Growth in the Medical MRI Market 3
(Date:11/28/2014)... The report “Poxvirus Infections Pipeline ... therapeutic development for Poxvirus Infections, complete with comparative ... target, mechanism of action (MoA), route of administration ... and featured news and press releases. It also ... for Poxvirus Infections and special features on late-stage ...
(Date:11/28/2014)... November 29, 2014 Recently, PrettyTailor.com has ... dresses for its customers around the world in celebration ... customers, PrettyTailor.com has also launched a special offer on ... more. , As a pioneer in the garment industry, ... products for clients large and small. The business carries ...
(Date:11/28/2014)... The holiday season is fast approaching. As a ... collection of fashionable party dresses. What’s more, the company is ... brand new outfits; the special offer is valid until Dec. ... supplier and it has received a lot of requests for ... designed to flatter various body shapes; they are available in ...
(Date:11/28/2014)... 28, 2014 Now that the holiday ... one of the nation's leading cash-for-junk-cars companies, is improving ... to be more competitive and help bring a little ... festive time of year. , Along with purchasing expensive ... the US also deal with large travel expenses during ...
(Date:11/28/2014)... 2014 Mirena lawsuits ( http://www.mirenalawsuit2014.com/ ... New Jersey’s Bergen County Superior Court, where the ... there is quickly approaching 1,300, Bernstein Liebhard LLP ... shows 1,293 lawsuits now pending in the consolidated ... complications resulting from spontaneous migration of the birth ...
Breaking Medicine News(10 mins):Health News:Poxvirus Infections and Vestibular Diseases Pipeline Market Drugs and Companies Review H2 2014 2Health News:Poxvirus Infections and Vestibular Diseases Pipeline Market Drugs and Companies Review H2 2014 3Health News:Poxvirus Infections and Vestibular Diseases Pipeline Market Drugs and Companies Review H2 2014 4Health News:2015 Wedding Dresses from PrettyTailor.com Available Now 2Health News:Trendy Party Dresses For The Coming Holiday Season From Balfleet.com 2Health News:Rusty's Auto Salvage Increasing Their Cash Offers to Help Drivers Save Throughout the Busy Holiday Season 2Health News:Nearly 1,300 Mirena Lawsuits Now Filed in Consolidated New Jersey Litigation, Bernstein Liebhard LLP Reports 2Health News:Nearly 1,300 Mirena Lawsuits Now Filed in Consolidated New Jersey Litigation, Bernstein Liebhard LLP Reports 3
... September 11, 2011, one of the most critical challenges that ... victims trapped under debris a painful and tedious race ... been a losing race when relying on drills, saws, and ... and Technology Directorate (S&T) has developed a new tool to ...
... Sept. 21, 2011 Patients at Virginia G. Piper Cancer ... participate in a clinical trial to determine the safety, tolerability ... proteins associated with the most common form of lung cancer, ... and neuroblastoma. The first patient on the study ...
... News) -- Differences in the genetic makeup of prostate cells ... more likely to get prostate cancer and die from it ... a lot of socioeconomic and environmental factors that create differences ... co-author Bi-Dar Wang, assistant research professor of pharmacology and physiology ...
... Administration of the commonly used stimulant drug methylphenidate (Ritalin) was ... study conducted at Massachusetts General Hospital (MGH). The report, ... the first demonstration in mammals of what could be a ... While there are drugs to counteract many of the ...
... NY) Researchers at Albert Einstein College of ... by rheumatologists and the use of immunosuppressant drugs improve the ... could reverse long-standing clinical practice. Their study appeared in the ... At least 1.5 million Americans (more than 90 ...
... Move over, gourmet meal. Apparently cold hard cash and a ... conclusion of new research that examined how people react when ... people salivate when they desire material objects, according to the ... Research . "Merely being exposed to the concept of ...
Cached Medicine News:Health News:Racing against time 2Health News:TGen-Virginia G. Piper Cancer Center launches clinical trial for drug to treat lung cancer 2Health News:Genes May Explain Blacks' Bleaker Prostate Cancer Stats 2Health News:Common stimulant may speed recovery from general anesthesia 2Health News:Common stimulant may speed recovery from general anesthesia 3Health News:Continued treatment for lupus may boost survival of those patients with end-stage kidney disease 2Health News:Cash, Luxury Goods Really Do Get People Salivating: Study 2
... Infinity Triglycerides powder reagent once reconstituted ... of single liquid stability to help ... and provide quick result turnaround time. ... Triglycerides powder reagent provides a long ...
... single liquid stable reagent offers the ... liquid stability to help maximize laboratory ... quick result turnaround time. The patented ... provides a long shelf life that ...
... Infinity Creatinine single liquid stable reagent ... of single liquid stability to help ... and provide quick result turnaround time. ... Creatinine reagent provides a long shelf ...
... Amylase powder reagent once reconstituted offers ... single liquid stability to help maximize ... provide quick result turnaround time. The ... powder reagent provides a long shelf ...
Medicine Products: